Table 3. Echocardiographic and plasma IGF-1 measurements before and after treatment of acromegaly.
| Echocardiographic parameter | Pre-treatment | Post-treatment | P value |
|---|---|---|---|
| Hypophysectomy group (n = 20) | |||
| IVSd (mm) | 5.9 (4.4–8.1) | 4.9 (3.6–6.6) | <0.001 * |
| LVFWd (mm) | 5.5 (4.2–8.9) | 4.9 (3.7–8.4) | 0.001 * |
| LVmax (mm) | 6.1 (4.4–8.9) | 5.2 (3.9–8.4) | 0.002 * |
| LA diameter (mm) | 16.3 (13.0–21.0) | 14 (11.5–16.6) | 0.001 * |
| LVIDd (mm) | 16.8 (11.9–19.2) | 15.1 (10.2–19.4) | 0.01 * |
| LV FS (%) | 43 (20–69) | 51 (36–74) | 0.117 |
| LA FS (%) | 28 (15–57) | 31 (18–58) | 0.627 |
| IGF-1 (ng/mL) | 1961 (1055–2000) | 85 (15–721) | 0.008 * |
| Pasireotide group (n = 9) | |||
| IVSd (mm) | 6.7 (5.5–8.0) | 6.1 (4.8–8.0) | 0.575 |
| LVFWd (mm) | 6.2 (5.8–8.2) | 5.8 (4.4–7.5) | 0.208 |
| LVmax (mm) | 6.7 (5.9–8.2) | 6.1 (5–8) | 0.575 |
| LA diameter (mm) | 17.4 (14.1–22.4) | 15.6 (11.8–19.3) | 0.028 * |
| LVIDd (mm) | 15.5 (12.6–17.7) | 15.9 (11.3–17.9) | 1.000 |
| LV FS (%) | 45 (41–60) | 47 (29–51) | 0.161 |
| LA FS (%) | 34 (27–60) | 31 (22–42) | 0.465 |
| IGF-1 (ng/mL) | 2000 (993–2000) | 1659 (18–2000) | 0.080 |
*indicates statistical significance at the 5% level